A Cost Analysis of Haemodialysis and Peritoneal Dialysis for the Management of End-Stage Renal Failure At an Academic Hospital in Pretoria, South Africa

Makhele, Letlhogonolo, Matlala, Moliehi, Sibanda, Mncengeli, Martin, Antony P ORCID: 0000-0003-4383-6038 and Godman, Brian ORCID: 0000-0001-6539-6972 (2019) A Cost Analysis of Haemodialysis and Peritoneal Dialysis for the Management of End-Stage Renal Failure At an Academic Hospital in Pretoria, South Africa. PHARMACOECONOMICS-OPEN, 3 (4). pp. 631-641.

Text Makhele2019_Article_ACostAnalysisOfHaemodialysisAn.pdf - Published version Download (844kB)

Abstract

<h4>Background</h4>Haemodialysis (HD) and peritoneal dialysis (PD) are commonly used treatments for the management of patients with end-stage renal disease (ESRD). The costs of managing these patients have grown in recent years with increasing rates of non-communicable diseases, which will adversely impact on national health budgets unless addressed. Currently, there is limited knowledge of the costs of ESRD within the public healthcare system in South Africa.<h4>Objective</h4>The aim of this study was to examine the direct costs of HD and PD in South Africa from a healthcare provider's perspective.<h4>Methods</h4>A prospective, observational study was undertaken at a leading public hospital in South Africa. A micro-costing approach was applied to estimate healthcare costs using 46 adult patients with ESRD who had been receiving HD and PD for at least 3 months.<h4>Results</h4>The highest proportion of patients (35%) were aged 40-50 years. Patients aged 29-39 years were mostly on HD (28% vs. 21% on PD) while those aged 51-59 years mostly used PD (29% vs. 16% on HD). The average age of patients on HD and PD were 41 and 42 years, respectively. Fixed costs were the principal cost driver for HD ($16,231.45) while variable costs were the principal cost driver for PD (US$20,488.79). The annual cost of HD per patient (US$31,993.12) was higher than PD (US$25,282.00 per patient), even though the difference was not statistically significant (p = 0.816).<h4>Conclusion</h4>HD costs more than PD from the provider's perspective. These cost estimates may be useful for carrying out future cost-effectiveness and cost-utility analyses in South Africa.

Item Type:	Article
Uncontrolled Keywords:	Aging, Neurodegenerative, Clinical Research, Kidney Disease, Brain Disorders, Cost Effectiveness Research, Health Services, Prevention, Renal and urogenital, 3 Good Health and Well Being
Depositing User:	Symplectic Admin
Date Deposited:	22 Mar 2019 09:57
Last Modified:	17 Mar 2024 03:19
DOI:	10.1007/s41669-019-0124-5
Related URLs:	Author Publisher
URI:	https://livrepository.liverpool.ac.uk/id/eprint/3034651